Ngozi Olejeme, Under Prosecution By EFCC for N1.3 Billion NSITF Fraud, Slumps, Trial Adjourned Till April 13

The trial of former Chairman of Nigeria Social Insurance Trust Fund (NSITF) Dr. Ngozi Olejeme could not continue on Monday March 28, 2021 because the defendant allegedly slumped at home.

According to her counsel, Paul Erokoro SAN, the defendant slumped at exactly 6:30 am today while getting set for court, and was rushed to the Federal Medical Centre Jabi, Abuja for medical attention.

The Economic and Financial Crimes Commission, EFCC is prosecuting Olejeme on a nine count charge bordering on criminal conspiracy, abuse of office, diversion of public funds and money laundering to the tune of over One Billion Naira.

The case is before Justice Maryam Hassan Aliyu of the Federal Capital Territory High Court, Jabi Abuja.

Erokoro presented a letter informing the court about the development and praying for an adjournment. He further told the court that he could not present a medical report as the hospital was still reviewing her case.

Responding, the prosecuting counsel, Sir Steve Odiase did not oppose the application for adjournment.  “My lord, they served us with a letter seeking for an adjournment based on the defendant’s ill health, and being the defendant’s first time absenting herself in the court and for the interest of justice, we are not opposing their application seeking adjournment.

“Meanwhile, for record purposes, we came prepared with five witnesses in court, and all of them stood up for recognition,” he said.

Justice Aliyu thereafter adjourned the matter till April 13, 2022, for continuation of trial.

Related posts

Man, 60, Charged With Murder After Body Of Woman Missing For 10-days Found At Home

2.1 Tons Cocaine Seizure: NDLEA Secures 28-years Jail Term For 4 Drug Lords, Forfeits VGC Houses, N67m, $50,000 Cash

Again, General Tiani Accuses France of Offering Funds to Nigeria for Destabilization Efforts in Niger, Neighboring Countries 

This website uses Cookies to improve User experience. We assume this is OK...If not, please opt-out! Read More